Mobic® — Meloxicam — NSAID — Oxicam Class — Anti-inflammatory & Analgesic
1. Disclaimer
This information is intended for educational and general reference purposes only and does not replace professional medical advice, diagnosis, treatment, a physician's prescription, or the official prescribing information supplied with the medicine. Meloxicam is a prescription non-steroidal anti-inflammatory drug (NSAID) with potentially serious gastrointestinal, cardiovascular, renal, hepatic, allergic, dermatologic and pregnancy-related risks. Treatment should be individualized by a qualified healthcare professional, using the lowest effective dose for the shortest appropriate duration.
We do not guarantee the accuracy, currency or completeness of information regarding medications or medical products, and official sources should be verified before making any decisions. Readers are responsible for independently verifying the information before relying on it.
Product formulations, manufacturers, marketing authorization holders, pack sizes, indications, age restrictions, storage requirements and approved prescribing information may differ between countries and may change over time. The current package leaflet and locally approved product information should therefore always be checked before prescribing, dispensing or using the medicine.
2. Summary
Mobic® contains meloxicam, a prescription non-steroidal anti-inflammatory drug belonging to the oxicam class. It has anti-inflammatory, analgesic and antipyretic effects and is primarily used for symptomatic treatment of inflammatory and degenerative musculoskeletal disorders, particularly osteoarthritis, rheumatoid arthritis and ankylosing spondylitis.
Meloxicam acts mainly by inhibiting cyclooxygenase-mediated prostaglandin synthesis. It does not cure the underlying rheumatic disease; instead, it reduces pain, inflammation, swelling and stiffness.
For the oral tablet formulation described in the supplied product information, usual doses are 7.5 mg or 15 mg once daily, with a maximum total daily dose of 15 mg. Patients at increased risk of adverse effects generally require the lowest effective dose. In patients with end-stage renal disease receiving haemodialysis, the dose should not exceed 7.5 mg/day.
As with all systemic NSAIDs, meloxicam can cause serious adverse reactions, including gastrointestinal ulceration or bleeding, cardiovascular thrombotic events, renal injury, hyperkalaemia, hepatotoxicity, severe allergic reactions and serious skin reactions. Current NSAID safety information also recognizes fetal renal dysfunction and oligohydramnios with exposure from approximately 20 weeks of pregnancy, in addition to the established late-pregnancy cardiovascular risk to the fetus.
3. Brand Name
Mobic®
The brand name Mobic has been used internationally for medicinal products containing meloxicam. Availability and formulations differ between markets.
Egyptian commercial and pharmacy listings consulted in 2026 report Mobic products containing meloxicam, including oral tablets and some non-oral presentations. These commercial reports do not establish current regulatory status or actual market availability and should not be regarded as a substitute for verification through the Egyptian Drug Authority.
4. Category
- Pharmacological class: Non-steroidal anti-inflammatory drug (NSAID)
- Chemical/therapeutic subclass: Oxicam
- ATC code: M01AC06
- Principal actions: Anti-inflammatory, analgesic and antipyretic
The supplied Mobic information identifies meloxicam as a non-steroidal anti-inflammatory agent of the oxicam group.
5. Active Ingredient
Meloxicam
Chemical name:
4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-carboxamide-1,1-dioxide
The supplied tablet formulation contains either 7.5 mg or 15 mg meloxicam per tablet.
6. Pharmaceutical Form & Strength
For the tablet product described in the supplied prescribing information:
- Mobic 7.5 mg tablets
- Mobic 15 mg tablets
Public Egyptian commercial and pharmacy listings consulted in 2026 report the following Mobic presentations:
- Mobic 15 mg tablets – pack of 30 tablets
- Mobic 7.5 mg tablets – pack of 10 tablets
- Mobic 15 mg/1.5 mL solution for injection – 5 ampoules
- Mobic 15 mg suppositories – pack of 6 suppositories
These are commercially reported presentations; their current regulatory status and actual market availability in Egypt should be verified through the Egyptian Drug Authority. The dose, route and approved indications of one pharmaceutical form should not automatically be applied to another formulation.
7. Manufacturer & Marketing Authorization Holder
The supplied Mobic product information states:
Manufactured by:
Boehringer Ingelheim Pharma GmbH & Co. KG
For:
Boehringer Ingelheim International GmbH
Ingelheim am Rhein, Germany.
Egyptian commercial drug listings also identify Boehringer Ingelheim as the producer associated with the Mobic products listed in that market.
The exact current marketing authorization holder and manufacturing site should nevertheless be confirmed from the package marketed in the relevant country or the current national regulatory record, because regulatory ownership and manufacturing arrangements may change.
8. Mechanism of Action
Meloxicam inhibits cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing biosynthesis of prostaglandins.
Prostaglandins participate in inflammation, pain sensitization and fever. Reducing their formation explains the anti-inflammatory, analgesic and antipyretic effects of meloxicam. Its mechanism, like that of other NSAIDs, is not limited to one single biochemical effect and is not completely understood.
Meloxicam should not be considered a completely COX-2-specific drug comparable with selective coxibs; clinically relevant inhibition of prostaglandin synthesis can still produce the gastrointestinal, renal, cardiovascular and platelet-related adverse effects characteristic of NSAIDs.
9. Spectrum of Activity
An antimicrobial “spectrum of activity” is not applicable to meloxicam.
Meloxicam is not an antibiotic, antifungal, antiviral or antiparasitic drug.
Its pharmacological activity consists principally of:
- Reduction of inflammation
- Relief of inflammatory and musculoskeletal pain
- Reduction of fever
- Reduction of inflammation-related joint swelling and stiffness
It does not eradicate an infectious organism and may, like other NSAIDs, partially mask symptoms such as pain or fever associated with an underlying infection.
10. Pharmacokinetics
Absorption
Meloxicam is well absorbed following oral administration. Absolute oral bioavailability is approximately 89–90%.
Following conventional oral solid dosage forms, peak plasma concentrations are generally reached after approximately 5–6 hours. Steady-state concentrations are typically reached within approximately 3–5 days of once-daily administration.
Food does not materially reduce the overall extent of meloxicam absorption.
Distribution
Meloxicam is highly bound to plasma proteins, principally albumin, at approximately 99%.
It penetrates into synovial fluid, where concentrations are approximately 40–50% of plasma concentrations.
Its apparent volume of distribution is relatively low.
Metabolism
Meloxicam undergoes extensive hepatic metabolism to pharmacologically inactive metabolites.
CYP2C9 plays an important role in its metabolism, with a smaller contribution from CYP3A4. Peroxidase-mediated pathways also contribute.
Elimination
Meloxicam is eliminated mainly as metabolites in approximately similar proportions through urine and faeces. Only very small amounts of unchanged meloxicam are excreted.
The elimination half-life is long, generally approximately 15–20 hours, which supports once-daily dosing.
Renal and Hepatic Impairment
Mild to moderate renal or hepatic impairment generally has limited effects on meloxicam pharmacokinetics, but advanced renal disease can increase the unbound fraction and increase toxicity risk.
In haemodialysis patients, the dose should not exceed 7.5 mg/day. Meloxicam is highly protein-bound and is not effectively removed by haemodialysis.
11. Indications
For the tablet formulation represented by the supplied product information, Mobic is indicated for:
- Short-term symptomatic treatment of exacerbations of osteoarthritis (osteoarthrosis).
- Long-term symptomatic treatment of rheumatoid arthritis.
- Long-term symptomatic treatment of ankylosing spondylitis.
Meloxicam provides symptomatic relief but does not alter or cure the underlying rheumatic disease.
Licensed indications may differ between jurisdictions and pharmaceutical forms. For example, some regulatory jurisdictions have separately approved certain meloxicam products for juvenile rheumatoid arthritis, while the tablet product information supplied here contraindicates this formulation in patients younger than 16 years. Therefore, indications and age limits should always follow the locally approved formulation-specific label rather than being extrapolated between products.
12. Administration
General Principle
Use the lowest effective dose for the shortest duration necessary to control symptoms.
The patient's need for treatment and response should be reassessed periodically, particularly during long-term treatment.
Osteoarthritis Exacerbation
7.5 mg once daily.
If the response is inadequate and treatment remains appropriate, the dose may be increased to:
15 mg once daily.
Rheumatoid Arthritis and Ankylosing Spondylitis
The supplied product information recommends:
15 mg once daily.
According to therapeutic response, this may be reduced to:
7.5 mg once daily.
Maximum Dose
Do not exceed 15 mg/day.
Higher-Risk Patients
Patients with increased risk of adverse reactions should generally start at 7.5 mg/day.
For long-term treatment of rheumatoid arthritis or ankylosing spondylitis in elderly patients, the supplied product information recommends 7.5 mg/day.
Renal Impairment
In patients with end-stage renal failure receiving haemodialysis:
Do not exceed 7.5 mg/day.
No dose reduction is generally required for mild to moderate renal impairment, although renal function and clinical condition must be considered carefully.
How to Take the Tablets
The total daily oral dose is taken as one dose per day with water or another liquid.
The supplied Mobic information advises taking it during a meal. Current pharmacokinetic data indicate that food does not materially alter the overall extent of absorption.
Dosing recommendations above refer to the oral tablet formulation. Injectable and suppository formulations have route-specific prescribing information and should not be dosed merely by converting the oral regimen milligram-for-milligram.
13. Method of Preparation
No preparation or reconstitution is required for the tablets.
They should be taken orally with water or another liquid according to the product-specific instructions.
Injectable preparations must be administered only by the appropriate route and according to their formulation-specific professional prescribing information.
Suppositories are intended for rectal administration and do not require oral preparation.
No dilution, mixing or extemporaneous preparation instructions for the oral Mobic tablets are required.
14. Contraindications
Meloxicam should not be used in patients with established contraindications including:
- Hypersensitivity to meloxicam or any formulation component.
- Previous asthma, nasal polyps, angioedema, urticaria or other serious hypersensitivity reaction precipitated by aspirin or another NSAID.
- Active gastrointestinal bleeding.
- History of gastrointestinal bleeding or perforation associated with previous NSAID therapy.
- Active or recurrent peptic ulcer or haemorrhage.
- History of cerebrovascular bleeding or other significant bleeding disorders where listed in the locally approved product information.
- Severe hepatic impairment.
- Severe renal failure in patients who are not receiving dialysis.
- Severe heart failure under the supplied European-style product information.
- Third trimester of pregnancy.
- Children and adolescents below 16 years for the tablet formulation represented by the supplied Mobic information.
Current U.S. systemic NSAID labeling additionally lists use in the setting of coronary artery bypass graft (CABG) surgery as contraindicated because of increased cardiovascular risk.
Contraindications should always be checked against the current locally approved prescribing information because wording differs between regulatory jurisdictions.
15. Warnings & Precautions
Gastrointestinal Risks
Meloxicam can cause gastrointestinal inflammation, ulceration, bleeding and perforation. These events may be severe or fatal and can occur without warning symptoms.
Risk is greater in patients with previous peptic ulcer or GI bleeding, the elderly, debilitated patients, those receiving high doses or prolonged treatment, and patients simultaneously using drugs such as anticoagulants, antiplatelet drugs, corticosteroids or SSRIs.
Stop treatment and seek urgent medical assessment if gastrointestinal bleeding or ulceration is suspected.
Cardiovascular and Cerebrovascular Risk
Systemic NSAIDs are associated with an increased risk of serious cardiovascular thrombotic events such as myocardial infarction and stroke. Risk can occur relatively early during treatment and becomes more concerning with higher doses and longer exposure.
Patients with established cardiovascular disease or cardiovascular risk factors require careful benefit-risk assessment.
Meloxicam may also cause or worsen hypertension, fluid retention and oedema.
Heart Failure
NSAIDs can worsen fluid retention and heart failure. Patients with heart failure require particular caution and clinical monitoring.
Renal Toxicity
NSAIDs reduce prostaglandin-dependent renal blood flow and can precipitate deterioration of renal function, particularly in patients with:
- Pre-existing renal impairment
- Dehydration or hypovolaemia
- Heart failure
- Severe liver disease
- Older age
- Concurrent ACE inhibitors, ARBs or diuretics
Acute renal failure and other renal injury can occur. Renal function and hydration should be monitored when clinically indicated.
Hyperkalaemia
NSAIDs can increase serum potassium. The risk may be higher with renal impairment, diabetes or concomitant medicines that raise potassium concentrations.
Hepatic Effects
Transient elevations in liver enzymes can occur. Rare severe hepatic injury has been reported with NSAIDs.
Meloxicam should be discontinued and evaluated if significant or persistent liver abnormalities or clinical signs of hepatic injury develop.
Serious Skin Reactions
Potentially life-threatening reactions including:
- Stevens-Johnson syndrome (SJS)
- Toxic epidermal necrolysis (TEN)
- Exfoliative dermatitis
- Fixed drug eruption (FDE)
- Generalized bullous fixed drug eruption
have been reported.
Meloxicam must be discontinued promptly if serious rash, blistering, mucosal lesions or other signs of severe hypersensitivity occur. Re-exposure should be avoided in patients with a previous meloxicam-associated fixed drug eruption.
DRESS
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has also been reported with NSAIDs including meloxicam and can be severe or life-threatening.
Possible manifestations include fever, rash, facial swelling, lymphadenopathy, eosinophilia and involvement of organs such as the liver or kidneys. Immediate discontinuation and medical assessment are required when suspected.
Anaphylaxis and Aspirin-Sensitive Asthma
Meloxicam may cause anaphylactic reactions, including in patients without previously documented hypersensitivity.
Patients with aspirin-sensitive asthma may experience severe bronchospasm because of cross-reactivity with other NSAIDs.
Pregnancy-Related Fetal Toxicity
NSAID use from approximately 20 weeks of gestation may cause fetal renal dysfunction leading to oligohydramnios and, occasionally, neonatal renal impairment.
If treatment between approximately 20 and 30 weeks is considered essential, it should be limited to the lowest effective dose and shortest duration. If treatment extends beyond about 48 hours, monitoring of amniotic fluid may be appropriate.
At approximately 30 weeks of pregnancy and later, NSAIDs should be avoided because of the additional risk of premature closure of the fetal ductus arteriosus.
Meloxicam is contraindicated during the third trimester under the European-style product information.
Haematological Effects
Anaemia and blood-cell abnormalities may occur, especially when there is occult bleeding or concomitant myelotoxic therapy.
Fertility
By inhibiting cyclooxygenase/prostaglandin synthesis, NSAIDs may delay ovulation and may reversibly impair female fertility. Discontinuation should be considered in women experiencing difficulty conceiving or undergoing fertility investigation.
Infection
Meloxicam may mask signs and symptoms of an underlying infection, particularly pain and fever.
Lactose
The supplied Mobic tablets contain lactose. Patients with relevant rare hereditary disorders of galactose metabolism or absorption should refer to the current product-specific prescribing information.
16. Drug Interactions
Drugs That May Promote Hyperkalaemia
Concomitant use with medicines that may increase serum potassium can further increase the risk of hyperkalaemia. These include potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists (ARBs), heparins (low-molecular-weight or unfractionated), ciclosporin/cyclosporine, tacrolimus and trimethoprim. Serum potassium should be monitored when clinically appropriate, particularly when additional risk factors are present.
Other NSAIDs and Aspirin
Avoid combining meloxicam routinely with other NSAIDs, including COX-2 inhibitors, because toxicity—particularly gastrointestinal toxicity—may increase without a corresponding therapeutic benefit.
Concomitant aspirin increases gastrointestinal and bleeding risk. Meloxicam is not a substitute for low-dose aspirin used for cardiovascular protection.
Anticoagulants and Antiplatelet Drugs
Warfarin, heparin, aspirin and other antiplatelet drugs can substantially increase bleeding risk when combined with meloxicam.
Clinical monitoring, including INR monitoring where relevant, may be required.
SSRIs and SNRIs
Drugs that interfere with serotonin-mediated platelet function can further increase bleeding risk when combined with an NSAID.
Corticosteroids
Systemic corticosteroids increase the risk of gastrointestinal ulceration and bleeding.
ACE Inhibitors, ARBs and Beta-Blockers
NSAIDs can reduce the antihypertensive effect of these medicines.
ACE inhibitors and ARBs combined with an NSAID can also increase the risk of renal deterioration, particularly in elderly, volume-depleted or renally impaired patients.
Diuretics
NSAIDs may reduce diuretic and antihypertensive efficacy and increase the risk of renal impairment.
Lithium
NSAIDs may increase lithium concentrations by reducing renal lithium clearance. Monitor for lithium toxicity and, when indicated, serum lithium concentrations.
Methotrexate
NSAIDs may reduce renal elimination of methotrexate and increase the risk of haematological, renal and other methotrexate toxicity. Particular caution is required with high-dose methotrexate and in patients with impaired renal function.
Ciclosporin/Cyclosporine and Tacrolimus
NSAIDs can increase nephrotoxicity associated with calcineurin inhibitors; renal function should be monitored.
Deferasirox
Concomitant administration of meloxicam and deferasirox may increase the risk of gastrointestinal adverse reactions. Caution is advised when these medicines are used together.
Mifepristone
NSAIDs should generally not be used for 8–12 days after mifepristone administration, because they may reduce the effect of mifepristone.
Quinolone Antibiotics
Concomitant use of NSAIDs and quinolone antibiotics may increase the risk of convulsions. Caution is advised in patients receiving both.
Zidovudine
Concomitant use of NSAIDs with zidovudine may increase the risk of haematological toxicity. Increased risks of haemarthrosis and haematoma have been reported in HIV-positive patients with haemophilia receiving zidovudine together with an NSAID.
Pemetrexed
Meloxicam may increase pemetrexed-associated bone-marrow, gastrointestinal and renal toxicity.
In patients with creatinine clearance approximately 45–79 mL/min, current labeling recommends interrupting meloxicam for at least 5 days before, on the day of, and for at least 2 days after pemetrexed administration.
Concomitant use is not recommended when creatinine clearance is below approximately 45 mL/min.
In patients with normal renal function (creatinine clearance ≥80 mL/min), 15 mg meloxicam may decrease pemetrexed elimination and increase the risk of pemetrexed-related adverse effects; caution is therefore advised when these medicines are co-administered.
Cholestyramine
Cholestyramine interrupts enterohepatic circulation and substantially accelerates elimination of meloxicam. This interaction is sufficiently strong that cholestyramine has also been studied as a means of increasing drug clearance following overdose.
Oral Antidiabetic Drugs
Current European product information advises awareness of potential CYP2C9-mediated interactions with drugs such as sulfonylureas and nateglinide, with monitoring for hypoglycaemia where clinically appropriate.
17. Side Effects
The most frequently reported adverse effects of meloxicam and other NSAIDs are gastrointestinal.
Possible adverse reactions include:
Gastrointestinal
- Dyspepsia
- Nausea
- Vomiting
- Abdominal pain
- Diarrhoea
- Constipation
- Flatulence
- Gastritis
- Stomatitis
- Gastrointestinal bleeding
- Peptic/gastroduodenal ulcer
- Colitis
- Oesophagitis
- Gastrointestinal perforation
- Pancreatitis — frequency not known
GI bleeding, ulceration and perforation may be severe or fatal, especially in elderly or high-risk patients.
Nervous System
- Headache
- Dizziness
- Somnolence
- Vertigo
- Tinnitus
- Rare visual disturbances
Cardiovascular
- Increased blood pressure
- Oedema/fluid retention
- Palpitations
- Worsening heart failure
- Serious arterial thrombotic events such as myocardial infarction or stroke
Blood and Immune System
- Anaemia
- Leukopenia
- Thrombocytopenia
- Rare agranulocytosis
- Allergic reactions
- Anaphylactic/anaphylactoid reactions
Hepatic
- Elevated transaminases or bilirubin
- Hepatitis
- Rare severe hepatic injury/failure
Renal
- Increased serum creatinine or urea
- Sodium and water retention
- Hyperkalaemia
- Acute renal failure
- Interstitial nephritis and other forms of renal injury reported with the NSAID class
Skin
- Rash
- Pruritus
- Urticaria
- Angioedema
- Photosensitivity
- Fixed drug eruption
- Erythema multiforme
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
Serious blistering, peeling, mucosal ulceration, facial swelling, breathing difficulty, black stools, vomiting blood, marked reduction in urine output, chest pain or sudden neurological symptoms require urgent medical assessment.
18. Use in Special Populations
Pregnancy
During early pregnancy, meloxicam should only be used when clearly necessary and under medical supervision.
From approximately 20 weeks, NSAID exposure can cause fetal renal dysfunction and oligohydramnios. If treatment between approximately 20 and 30 weeks is unavoidable, use the lowest dose for the shortest possible time.
From approximately 30 weeks onward, NSAIDs should be avoided because of fetal ductus arteriosus constriction/closure risk.
Meloxicam is contraindicated during the third trimester according to the supplied and European-style product information.
Breastfeeding
Human data for meloxicam during lactation are limited.
European product information states that administration is not recommended during breastfeeding. Current U.S. labeling notes the absence of adequate human milk data and recommends balancing the mother's clinical requirement against potential effects on the breastfed infant.
Fertility
Meloxicam may reversibly impair ovulation and is generally not recommended in women attempting to conceive.
Elderly
Older adults have increased susceptibility to serious NSAID-related gastrointestinal, renal and cardiovascular adverse effects.
Use the lowest effective dose, monitor carefully, and consider 7.5 mg/day for long-term treatment when appropriate.
Renal Impairment
No routine dose reduction is generally required in mild to moderate renal impairment, but renal function should be monitored according to clinical risk.
Severe renal impairment without dialysis is a contraindication in the supplied European-style information.
In haemodialysis patients, do not exceed 7.5 mg/day.
Hepatic Impairment
No routine dose reduction is generally required for mild to moderate hepatic impairment.
Severe hepatic impairment is a contraindication in the supplied product information, and patients with hepatic disease require appropriate monitoring.
Children and Adolescents
The supplied Mobic tablet information contraindicates the product in patients younger than 16 years.
Other meloxicam formulations in some jurisdictions have different paediatric approvals; these should not be extrapolated to the Mobic tablet product described here.
19. Storage Conditions
For the supplied Mobic tablet product:
- Store below 30°C.
- Store in the original package to protect from moisture.
- Keep out of the reach of children.
Storage instructions vary among manufacturers and markets; for example, some currently authorized generic meloxicam tablets specify storage below 25°C. The storage conditions printed on the actual marketed pack therefore take precedence.
20. Additional Sections
Overdose
Acute NSAID overdose may cause:
- Lethargy
- Drowsiness
- Nausea
- Vomiting
- Epigastric pain
- Gastrointestinal bleeding
Severe poisoning may cause:
- Hypertension
- Acute renal failure
- Hepatic dysfunction
- Respiratory depression
- Convulsions
- Coma
- Cardiovascular collapse
- Cardiac arrest
There is no specific antidote.
Treatment is principally supportive and symptomatic. Because meloxicam is highly protein-bound, haemodialysis is unlikely to provide meaningful removal.
Cholestyramine has been demonstrated to accelerate meloxicam elimination and may be considered in appropriate overdose management under medical supervision.
Driving and Operating Machinery
Meloxicam usually has little or no direct effect on ability to drive, but patients experiencing:
- Dizziness
- Drowsiness
- Vertigo
- Visual disturbances
- Other central nervous system effects
should avoid driving or operating machinery until these effects have resolved.
Monitoring
Depending on the patient's clinical circumstances, monitoring may include:
- Blood pressure
- Renal function
- Serum potassium
- Liver function tests
- Haemoglobin/haematocrit
- Signs of gastrointestinal bleeding
- Fluid retention or worsening heart failure
- Relevant interacting-drug concentrations or laboratory tests
Long-term treatment should be periodically reassessed to ensure that continued benefit outweighs risk.
21. Frequently Asked Questions (FAQ)
What is Mobic?
Mobic is a brand of meloxicam, a prescription NSAID used primarily to reduce pain and inflammation associated with certain joint and musculoskeletal diseases.
Is Mobic a painkiller?
Yes. Meloxicam has analgesic activity, although it is primarily classified as an NSAID. It also reduces inflammation and fever.
Is Mobic an antibiotic?
No. It has no antibacterial, antiviral or antifungal activity.
How often is Mobic taken?
Conventional meloxicam tablets are generally taken once daily because of the drug's relatively long elimination half-life.
What is the maximum tablet dose?
For adults using the conventional tablet product described here:
15 mg per day is the maximum recommended dose.
Higher doses increase toxicity and should not be used merely because symptoms remain uncontrolled.
Can Mobic be taken with ibuprofen, diclofenac, naproxen or another NSAID?
Usually no unless specifically instructed by a healthcare professional. Combining systemic NSAIDs increases gastrointestinal and other toxicities without reliably improving efficacy.
Can Mobic be taken with aspirin?
The combination can increase bleeding and gastrointestinal complications. Low-dose aspirin prescribed for cardiovascular protection should not be stopped or combined with meloxicam without advice from the prescribing clinician.
Is Mobic safe for the stomach?
No NSAID is free of gastrointestinal risk. Meloxicam can cause ulceration, bleeding or perforation, including potentially fatal events.
Can Mobic affect the kidneys?
Yes. It can impair renal blood flow and cause or worsen renal dysfunction, particularly in elderly, dehydrated, heart-failure or kidney-disease patients and in patients taking certain antihypertensive drugs or diuretics.
Can Mobic raise blood pressure?
Yes. NSAIDs can cause new or worsening hypertension and may reduce the effectiveness of some antihypertensive medicines.
Can Mobic be used during pregnancy?
It should be avoided unless specifically considered necessary by a healthcare professional.
Particular concern begins at approximately 20 weeks of pregnancy because of fetal renal and amniotic-fluid effects. It should generally be avoided at approximately 30 weeks and later, and it is contraindicated during the third trimester under the supplied product information.
Can Mobic be used while breastfeeding?
Current European-style product information does not recommend meloxicam during breastfeeding. Human lactation data remain limited.
Can Mobic be used in severe kidney disease?
Severe non-dialysed renal impairment is a contraindication under the supplied information. For patients on haemodialysis, the daily dose should not exceed 7.5 mg.
Can Mobic cause serious allergic or skin reactions?
Yes. Rare but potentially life-threatening reactions including anaphylaxis, SJS, TEN, fixed drug eruption and DRESS have been reported. Treatment should be stopped and urgent medical evaluation obtained if serious hypersensitivity symptoms develop.
Should Mobic be taken for as long as pain continues?
Not automatically. NSAIDs should be used at the lowest effective dose for the shortest appropriate duration, and continued treatment should be periodically reassessed.
22. References
- Mobic® supplied package/product information – Boehringer Ingelheim; tablet strengths, composition, pharmacology, pharmacokinetics, indications, contraindications, precautions, interactions, pregnancy, adverse effects, dosage, overdose, storage and manufacturer information. The supplied document identifies its package-insert date as April 2009.
- Electronic Medicines Compendium (emc): Meloxicam 15 mg Tablets – Summary of Product Characteristics. Current listing contains dosing, contraindications, interactions, serious skin-reaction information, pharmacology and special-population guidance.
- DailyMed: Meloxicam Tablets – U.S. prescribing information. Current information includes cardiovascular and gastrointestinal warnings, renal toxicity, hyperkalaemia, anaphylaxis, serious skin reactions, DRESS, fetal toxicity, pharmacokinetics, interactions and use in specific populations.
- U.S. Food and Drug Administration (FDA): NSAID Drug Safety Communication – pregnancy at 20 weeks or later. NSAID exposure from approximately 20 weeks may cause fetal renal dysfunction and oligohydramnios; treatment between approximately 20 and 30 weeks should be minimized when unavoidable and NSAIDs should be avoided at approximately 30 weeks and later.
- Therapeutic Goods Administration (Australia): MOBIC meloxicam product registrations. Mobic 7.5 mg and 15 mg products containing meloxicam are documented in the Australian Register of Therapeutic Goods under Boehringer Ingelheim.
- Egyptian commercial medicine/pharmacy listings, consulted in 2026: publicly accessible listings report Mobic 7.5 mg tablets, Mobic 15 mg tablets, Mobic 15 mg/1.5 mL ampoules and Mobic 15 mg suppositories. These commercial sources do not by themselves establish current regulatory status or actual market availability.
- Egyptian Drug Authority (EDA): Inquire about the Availability of Pharmaceutical Products. The official EDA service allows citizens to request confirmation of the availability of pharmaceutical products in the Egyptian market.